Global MicroRNA Market

MicroRNA Market Size, Share, Growth Analysis, By Products & Services(Services [Type (Isolation & Purification, miRNA cDNA Synthesis, Profiling, Localization), By Application(Cancer, Infectious Diseases, Immunological Disorder, Cardiovascular Disease), By End-use(Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes, Others), By Region - Industry Forecast 2024-2031


Report ID: SQMIG35H2216 | Region: Global | Published Date: September, 2024
Pages: 157 | Tables: 61 | Figures: 75

MicroRNA Market Dynamics

MicroRNA Market Drivers

Increased Public and Corporate Funding in Genomic Research 

  • Public and corporate funding in genomic research is opening new benefits in the microRNA industry. There is increased funding for conducting research in how microRNAs regulate gene functions and the development of illness. Such funding fast-tracks the creation of diagnostics and treatments through microRNA bases, and it facilitates innovation and cooperative research projects, thereby establishing their use in clinical settings. 

Enhanced Understanding and Application of Biomarkers 

  • MicroRNAs are gaining more importance as non-invasive biomarkers, and the medical profession and scientists are slowly realizing that biomarkers hold the key to the early detection and monitoring of disease conditions. MicroRNAs, being stable in body fluids, represent an ideal solution for diagnostic purposes and a representation of diseased condition. Growing awareness is thereby driving the demand for microRNA-based assays that will help to provide critical information regarding disease conditions and responses to treatment. 

MicroRNA Market Restraints  

Complex microRNA Biology 

  • MicroRNA biology is also complex, partly because it involves mode of action, mode of interaction with other biological components, and variability from different tissues. This complexity may delay pinpoint identification of specific treatment targets and translate scientific findings into practice somewhat harder, thus threatening the growth of the microRNA market. 

Market Fragmentation 

  • This fragmentation of the microRNA industry, with many companies driving in different directions to research, diagnose, and treat microRNA, will make it difficult for end consumers to make the best choices, which again leads to inconsistencies in the quality and reliability of products. It may further complicate the formation of standardized microRNA applications in the clinical environment and problematize working teams.
$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

MicroRNA Market size was valued at USD 1.20 billion in 2022 and is poised to grow from USD 1.35 billion in 2023 to USD 3.58 billion by 2031, growing at a CAGR of 12.90% during the forecast period (2024-2031).

The global microRNA industry is characterized by several competitors who are escalating their fight to capture market shares and gain a competitive edge. Research and development activities aimed at discovering new microRNA biomarkers, therapeutic targets, and diagnostic tools are driving the industry. Therefore, rivalry among market players is escalating too since such discoveries are promoting the development of new products and services based on microRNAs. Major players in the microRNA market include contract research firms, government and university research facilities, and biotechnology and pharmaceutical corporations. These organizations maintain the market via in-depth research, clinical studies, and commercialization of microRNA-based products. 'Thermo Fisher Scientific, Inc. (US) ', 'QIAGEN (Germany) ', 'NanoString Technologies, Inc. (US) ', 'Merck KGaA (Germany) ', 'Takara Bio, Inc. (Japan) ', 'BioGenex (US) ', 'GeneCopoeia, Inc. (US) ', 'New England Biolabs (US) ', 'Agilent Technologies, Inc. (US) ', 'Illumina, Inc. (US) ', 'Abcam plc (UK) ', 'Roche Holding AG (Switzerland) ', 'Arcturus Therapeutics Ltd. (US) ', 'Synthego Corporation (US) ', 'Bio-Techne Corporation (US) ', 'F. Hoffmann-La Roche Ltd. (Switzerland) ', 'Asuragen, Inc. (US) ', 'Cell Signaling Technology, Inc. (US) ', 'Molecular Cloud (China) ', 'Ribomed Biotechnologies, Inc. (US) ', 'Sirnaomics Inc. (US)'

Public and corporate funding in genomic research is opening new benefits in the microRNA industry. There is increased funding for conducting research in how microRNAs regulate gene functions and the development of illness. Such funding fast-tracks the creation of diagnostics and treatments through microRNA bases, and it facilitates innovation and cooperative research projects, thereby establishing their use in clinical settings. 

Development of Combination Therapies: Major microRNA market trends include combination therapies. There is a growing trend wherein more emphasis is being laid down on combination therapy that consists of using a classical treatment in combination with a microRNA-based treatment. Researchers are looking into how they can better improve treatment outcomes and surmount drug resistance through the potential use of microRNAs in interfering with a multiplicity of pathways or enhancing the effectiveness of drugs already available on the market. As such, the trend tends to be more holistic where instead of targeting one pathway, the drugs and therapeutic approaches manage to achieve therapeutic gain through the exploitation of unique properties of microRNAs. 

The microRNA market outlook highlighted that in 2023, the market was dominated by North America. This is so because growth in the region of microRNA is attributed to a number of factors, such as availability of significant population of major players in the area; some of which are Merck KGaA., NanoString Technologies, Inc., and Thermo Fisher Scientific, besides others whose expenditure on R&D has increased with them trying to come up with more advanced and innovative products. In 2023, the US accounted for the highest market share in North America. Some of the prominent players of the market with headquarters based in the US are Thermo Fisher Scientific, Merck KGaA., and QIAGEN. Distribution networks form the backbone of these players. The country enjoys simple access to miRNA services and products. 

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global MicroRNA Market

Report ID: SQMIG35H2216

$5,300
BUY NOW GET FREE SAMPLE